Authors: Amin SA, Lin C, Ganti AK, Zhen WK, Zhang C.
DOI: 10.3389/fonc.2025.1652522
Abstract Summary
Intermediate dose escalation of radiotherapy (64-74 Gy vs standard 60 Gy) provides no survival benefit for stage III unresectable NSCLC patients receiving immunotherapy after chemoradiation. Analysis of 4,947 patients showed standard dosing was equally effective when immunotherapy started >6 weeks post-treatment, suggesting dose intensification is unnecessary in this setting.
Why Brain? ๐ง
Higher RT doses don’t improve survival in stage III NSCLC when immunotherapy follows chemoradiation, supporting standard 60Gy dosing and sparing patients unnecessary toxicity.
Study Limitations:
Retrospective design using national cancer database
Observational study design
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
